All In Biotech

Drug Trial Radar · NCT05121714

Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464

A Two Part, Fixed-sequence, Open-label Crossover Study to Evaluate Potential CYP1A2-mediated Drug-drug Interactions of ABX464 in Healthy Subjects Using Caffeine and Fluvoxamine as Probe Drugs

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

59

Actual

Start

Dec 17, 2020

Primary completion

May 18, 2021

Study completion May 18, 2021

Sponsor

Lead sponsor
Abivax S.A.Industry
Sponsor type
Industry
First posted
Nov 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Crossover
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A two part, fixed-sequence, open-label crossover study to evaluate potential CYP1A2-mediated drug-drug interactions of ABX464 in healthy subjects using caffeine and fluvoxamine as probe drugs

Conditions

  • Healthy

Interventions

  • CaffeineDrug

    This is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 substrate (caffeine)

  • ABX464Drug

    This is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 inhibitor (fluvoxamine) and a known CYP1A2 substrate (caffeine).

  • FluvoxamineDrug

    This is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 inhibitor (fluvoxamine).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A - Day 1 Peak Plasma Concentration of CaffeineTime frame: Day 1
  2. Part A - Day 4 Peak Plasma Concentration (Cmax) of Caffeine & ABX464Time frame: Day 4
  3. Part A - Day 17 Peak Plasma Concentration (Cmax) of Caffeine & ABX464Time frame: Day 17
  4. Part A - Day 1 AUC of CaffeineTime frame: Day 1
  5. Part A - Day 4 AUC of Caffeine & ABX464Time frame: Day 4
  6. Part A - Day 17 AUC of Caffeine & ABX464Time frame: Day 17
  7. Part B - Day 1 - Peak Plasma Concentration of ABX464Time frame: Day 1
  8. Part B - Day 11 - Peak Plasma Concentration of ABX464Time frame: Day 11
  9. Part B - Day 1 - Area Under the Plasma Concentration Versus Time Curve (AUC)Time frame: Day 1
  10. Part B - Day 11 - Area Under the Plasma Concentration Versus Time Curve (AUC)Time frame: Day 11

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Simbec-Orion

    Merthyr Tydfil, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.